



22 December 2006

US Securities and Exchange Commission Office of International Corporate Finance 100 F Street, N.E.

WASHINGTON DC 20549

USA

Mailstop: Room 3628



Dear Sirs

Re: Submission by Mesoblast Limited under Rule 12g3-2(b) - SEC File Number 82-34929

We enclose copies of all documents lodged with the Australian Securities Commission on behalf of Mesoblast Limited for filing with the US Securities & Exchange Commission.

These lodgements date from 2 December to the present date 22 December 2006.

Yours sincerely

Kevin Hollingsworth Company Secretary **PROCESSED**

JAN 1 8 2007

THOMSON FINANCIAL


Level 39, 55 Collins Street Melbourne Victoria 3000 AUSTRALIA

+61 3 9639 6036

f +61 3 9639 6030

www.mesoblast.com

ABN 68 109 431 870 ACN 109 431 870



MESOBLAST RECEIVES FDA CLEARANCE FOR PHASE 2 STEM CELL CLINICAL TRIAL

Key points:

- . US FDA clears Mesoblast's IND submission for spinal fusion clinical trial
- First FDA-cleared allogeneic (unrelated recipient or off-the-shelf) stem cell product to begin trials in a spinal clinical indication
- FDA clearance validates Mesoblast's manufacturing, preclinical and clinical strategies
- Spinal fusion is first of multiple planned IND submissions to the FDA for additional clinical trials in major global market opportunities.

Melbourne, Australia; 18 December 2006: Australia's adult stem cell company, Mesoblast Limited (ASX:MSB), today announced that the United States Food and Drug Administration (US FDA) has cleared its Investigational New Drug Submission (IND) to commence a Phase 2 clinical trial for spinal fusion in the US.


Mesoblast Founder and Chief Scientific Adviser, Professor Silviu Itescu, said: "This is a major milestone for Mesoblast as clearance of our IND submission by the FDA validates the company's preclinical and clinical strategies for developing well-characterised, safe, and effective adult stem cell products.

"FDA clearance is a significant step towards commercialising our stem cell products in the major US market," Professor Itescu added.

Mesoblast's commercial strategy is to generate a series of high margin stem cell products that are obtained from a single donor, commercially expanded and frozen, and subsequently used in hundreds to thousands of unrelated, or allogeneic, recipients at the time and place of need.

Mesoblast is developing allogeneic (unrelated recipient) stem cell products for treatment of various medical conditions, including long bone fractures and degenerative intervertebral disc disease, both rapidly growing, billion dollar markets. In preclinical studies, Mesoblast's stem cells have generated statistically superior long bone repair and spinal fusion compared with controls.

Professor Itescu said this Phase 2 trial would be the first ever to test allogeneic, or 'off-the- shelf', adult stem cells for the treatment of spinal disc disease.



"The results of the trial will be used to support a pivotal Phase 3 clinical trial of Mesoblast's patented technology for spinal fusion, aiming to eliminate the need for autograft (or patient's own hip bone graft), reduce complications associated with existing treatment regimens, and improve fusion outcomes", he said.

During the conduct of the Phase 2 spinal fusion trial, Mesoblast will continue to work closely with several major international medical device companies, with a view to establishing strategic alliances for product sales and distribution at the most appropriate time.

About Mesoblast

Mesoblast Limited (ACN 109 431 870) is an Australian biotechnology company committed to commercialisation of novel treatments for orthopaedic conditions, including a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Mesoblast has worldwide exclusive rights to a series of patents and technologies that have been developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The company has a substantial equity holding in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and rapid product commercialisation.


For further information, please contact:

Julie Meldrum
Corporate Communications Director
Mesoblast Limited

T: + 61 (03) 9639 6036 M: +61 (0) 419 228 128

E: julie.meldrum@mesoblast.com

W: www.mesoblast.com



MESOBLAST TELEVISION COVERAGE

Melbourne, Australia; 4 December 2006: Australian adult stem cell company, Mesoblast Limited (ASX:MSB), today confirmed that a news item broadcast on Channel 9 last night focused on its adult stem cell platform technology.

The news item highlighted a live stem cell surgical procedure using Mesoblast technology and the latest generation catheter mapping system for stem cell delivery from Johnson & Johnson's Cordis Corporation. It also included an interview with Mesoblast's Chief Scientific Adviser, Professor Silviu Itescu.

The highlighted procedure was performed under a local anaesthetic at the John Hunter Hospital in NSW, Australia, on 1 December 2006. The procedure was televised live to an international gathering of leading cardiologists attending the Asia Pacific Interventional Advances Conference (APIA) in Sydney.

According to interventional cardiologist and Hunter Medical Research Institute researcher Dr Suku Thambar who performed the procedure, the patient is progressing well and was discharged from the John Hunter Hospital yesterday.


The procedure is part of a Pilot Clinical Trial over a 12-month period that commenced early in 2006. The aims of the Trial of up to 10 patients suffering from severe coronary artery disease are to determine safety and to confirm Mesoblast's Standard Operating Procedures for the manufacture and delivery of adult stem cells in a clinical setting.

In line with clinical trial protocols and The Privacy Act, patient details will not be released.

Millions of people worldwide suffer from severe coronary artery disease. Mesoblast's adult stem cell technology aims to grow new heart tissue and create new blood supply to improve cardiac function.

About Mesoblast

Mesoblast Limited (ACN 109 431 870) is an Australian biotechnology company committed to commercialisation of novel treatments for orthopaedic conditions, including a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Mesoblast has worldwide exclusive rights to a series of patents and technologies that have been developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and rapid product commercialisation.



For further information, please contact:

Julie Meldrum Corporate Communications Director Mesoblast Limited

T: + 61 (03) 9639 6036 M: +61 (0) 419 228 128

E: julie.meldrum@mesoblast.com

W: www.mesoblast.com

ASX Code	Company Name
AVV	AAV Limited
ACR	Acrux Limited
AED	AED Oil Limited
AMH	AMCIL Limited
AEZ	APN European Retail Trust
APD	APN Property Group
ARO	Astro Diamond Mines NL
AHS	Atlas Group Holdings Limited
ACD	Australian Central Credit Union Limited
AEU	Australian Education Trust
AFI	Australian Foundation Investment Company Limited
BAS	Bass Strait Oil Company Limited
BEC	Becton Property Group Limited
BTA	Biota Holdings Limited
BSL	BlueScope Steel Limited
CNP	Centro Properties Group
CER	Centro Retail Trust
CHR	Chalmers Limited
CCU	Cobar Consolidated Resources Limited
CGS	CogState Limited
CGJ	Coles Group Limited
CKL	Colorpak Limited
CMP	Compumedics Limited
CEU	ConnectEast Group
CSE	Copper Strike
CYN	CyGenics Limited
CYT	Cytopia Limited
DKS	Danks Holdings Limited
DJW	Djerriwarrh Investments Limited
EMB	Embelton Limited
FLK	Folkestone Limited
FRR	Frigrite Limited
GLE	GLG Corp Ltd
GMI	Global Mining Investments Limited
GLB	Globe International Limited
GNL	Great Gold Mines NL
HSN	Hansen Technologies Limited
HSP	Healthscope Limited
IPL	Incited Pivot Limited
IFL	IOOF Holdings Limited
IRE	IRESS Market Technology Limited
JGL_	Jackgreen Limited
JST	Just Group Limited
KGL	Kentor Gold
MTU	M2 Telecommunications
MPI	Mark Sensing Limited
MYP	Mayne Pharma Limited

MLB	Melbourne IT Limited
MSB	Mesoblast Limited
MEO	Methanol Australia Limited
MIR	Mirrabooka Investments Limited
MOG	Moby Oil & Gas
MPO	Molopo Australia Limited
MNY	Money3 Corporation Limited
MYF	Myer Group Finance Limited
NAE	New Age Exploration
NEU	Neuren Pharmaceuticals
NHM	New Holland Mining
NCM	Newcrest Mining Limited
OMP	OAMPS Limited
OFG	Over Fifty Group Limited
ORI	Orica Limited
OXR	Oxiana Limited
PBB	Pacifica Group Limited
PEK	Peak Resources Limited
PSH	Penrice Soda Holdings
PPS	Praemium Limited
PLF	Primelife Corporation Limited
PME	Pro Medicus Limited
PHA	
QUR	Public Holdings Australia Limited Quantum Reources Limited
RAB	
RRL	Rabinov Diversified Property Trust
RAU	Regis Resources Limited
SDI	Republic Gold Limited SDI Limited
SIP	
SIU	Sigma Pharmaceuticals Limited Sirius Telecommunications Limited
SSX	
SBC	Smorgon Steel Group Ltd
	Southern Cross Broadcasting Australia Limited
SRZ	Stellar Reources Limited
SHE	Stonehenge Metals Limited
STV	Sunraysia Television Limited
SYB	Symbion Health Tabour Heldings Limited
TAH	Tabcorp Holdings Limited
TIM	Tasmania Mines Limited
TLS	Telstra Corporation Limited
TRS	The Reject Shop Limited
UXC	UXC Limited
VGP	Verticon Group
VGH	Vision Group
VSL	Vision Systems Limited
WCB	Warrnambool Cheese & Butter Factory Co Holdings Limited
WLL	Wellcom Group
WSS	Working Systems Solutions